Methods of measuring potential for therapeutic potency and defining dosages for autologous cell therapies
AssigneeBioCardia, Inc.
InventorsPeter Altman, Cheryl Wong Po Foo
Life of this patent
Estimating the term…
Abstract
Autologous bone marrow cells (BMC) are transplanted to a heterologous site in a patient after a sample of the patient's BMC has been tested and found to have a phenotypic profile which meets minimum criteria for transplantation. The phenotypic profile may be obtained by screening a sample of bone marrow cells (BMC) from the patient for the phenotypic profile, such as a CD profile, the phenotype profile may be assessed to determine the likelihood that the BMC will be suitable for transplantation to the heterologous tissue site without enriching particular phenotypic population(s) of the BMC.
Claims7
A method for screening a patient to determine a likelihood that the patient's autologous bone marrow cells will be suitable for transplantation to a heterologous tissue site, said method comprising
- providing a sample of bone marrow cells (BMC) from the patient;
- obtaining a phenotypic profile of the BMC in the sample, wherein the phenotypic profile comprises a CD profile comprising the concentrations of at least CD19+, CD34+, and CD133+ cells;
- and
- assessing the phenotype profile to determine the likelihood that the BMC will be suitable for transplantation to the heterologous tissue site without enriching particular phenotypic population(s) of the BMC.
Dependencies are inferred from the claim text.